Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generics

Set Alert for Generics

ANI Brings In Record Revenues As Cortrophin Rollout Ploughs Ahead

ANI Pharmaceuticals has recorded its highest-ever quarterly revenue of $73.9m during Q2, following the launch of its cortrophin gel and a substantial growth in generics revenue.

Sales & Earnings Launches

Entry Deadline Looms For GGB Awards

There is now just one week to go until the 19 August deadline for companies to submit entries for the Global Generics & Biosimilars Awards 2022, which returns to Frankfurt this November.

Generic Drugs Biosimilars

UK Alendronate Prices Explode In July

An average price rise of over 1,400% was seen for alendronate 70mg tablets in the UK last month, as average prices for a host of other generics more than doubled.

Market Intelligence Pricing Strategies

Hikma Will Push Harder To Make M&A Happen

Following a challenging first half for Hikma, executive chairman and CEO Said Darwazah talks to Generics Bulletin about how the firm is planning to be more active in making deals happen, as well as how it plans to address pressures on its Generics division that led to two consecutive downgrades in guidance this year.

Strategy M & A

Amneal Expects Host Of New Launches To Drive Firm To Success

Despite a couple of setbacks during Q2, Amneal has sustained continual growth across its business, particularly in the injectables space.

Sales & Earnings Launches

Mayne And Mithra Obtain Long-Awaited NuvaRing Nod From FDA

Following a trio of complete response letters received since late 2018, Mayne Pharma and partner Mithra Pharmaceuticals have finally obtained US FDA approval for a generic version of Organon’s NuvaRing vaginal hormonal contraceptive ring.

Approvals Generic Drugs

Hikma Eyes Return To Growth After Further Cutting Generics Forecasts

Hikma has once again downgraded its expectations for its generics business in 2022 as it revealed a first-half drop of 18% in sales for the unit. However, injectables and branded increases helped to offset the decline, while the company maintained that generics growth was on the horizon in 2023.

Strategy Sales & Earnings

FDA Directs On Glenmark’s Ryaltris With New Batch Of Guidances

A batch of four dozen new and revised product-specific guidances for generic products has been published by the US Food and Drug Administration, spanning a range of routes, dosages, and therapeutic areas.

Generic Drugs Guidance Documents

One Year On, FDA Generic Drug Cluster Focuses On Facilitating Collaboration

Following its inaugural year, the FDA’s Generic Drug Cluster has formed data sharing arrangements concerning a number of vital indications.

Generic Drugs Review Pathway
See All
UsernamePublicRestriction

Register